A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas

Trial Profile

A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Alisertib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2017 Status changed from active, no longer recruiting to discontinued.
    • 11 Jul 2017 Status changed from suspended to active, no longer recruiting.
    • 11 Jul 2017 Planned End Date changed from 1 Jan 2021 to 12 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top